AbbVie and Gedeon to develop dopamine receptor modulators for the treatment of neuropsychiatric diseases

(RTTNews) – AbbVie (ABBV) and Gedeon Richter Plc. have collaborated to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases, AbbVie said in a statement.

The collaboration is based on the results of preclinical research conducted by Richter and includes several new chemical entities selected for development.

AbbVie and Richter have worked together for 15 years on central nervous system projects, including globally launched products such as cariprazine.

Under the terms of the agreement, the collaboration includes preclinical and clinical R&D activities with funding shared by the parties. Richter will receive an upfront cash payment, as well as potential future development, regulatory and commercial milestones.

Additionally, Richter may also receive royalties based on sales. AbbVie will have worldwide marketing rights, except for Richter’s traditional markets, such as geographic Europe, Russia, other CIS countries and Vietnam.

The transaction is expected to close in the second quarter of 2022.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button